National Vision Holdings, Inc. ( EYE) Q4 2025 Earnings Call March 4, 2026 8:30 AM EST Thank you for standing by, and welcome to National Vision's Fourth Quarter and Fiscal 2025 Earnings Conference ...
BridgeBio reported phase 3 top-line results for infigratinib, an oral drug for achondroplasia, showing strong efficacy and safety, and posing a competitive challenge to BioMarin's approved Voxzogo. On ...
Applied Digital's sales rose by 250% in its fiscal 2026 second quarter. Its expenses rose by 230%, and the company is still unprofitable. Applied Digital's stock is expensive, and the tech sector's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results